N/A N=41 Home Administration of FluMist by Parents/Caregivers
Influenza
Primary: Number of Subjects That Reported Successful Home Vaccination With no Adverse Events — 41 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=200 A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.
Anemia
Primary: Percentage of Participants Maintaining Average Hemoglobin Concentration Within +- 1 Gram/Deciliter of Their Reference Hb and Between 10.5 and 12.5 Gram/Deciliter During…
Phase 3 N=304 5% Topical Ibuprofen (IBU) for Ankle Sprain
Ankle Injuries
Primary: Sum of Pain Intensity Difference (SPID) on Weight Bearing Over 3 Days (SPID WB0-3) — 188.9; 173.6; 165.9 units on a scale — p=0.190
Phase 4 N=30 Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults
Major Depressive Disorder · Back Pain · Aged
Primary: Change in Montgomery Asberg Depression Rating Scale(MADRS) Score From Baseline and 12 Weeks — -11.7 units on a scale
Phase 3 N=204 Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device — 15.0; 14.8 micrograms/milliliter (µg/mL)
Phase 3 N=66 Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID
Primary Immunodeficiency Diseases (PID)
Primary: Annual Rate of Serious Bacterial Infections — 0.020 Estimated infections/year — p=<0.0001
N/A N=323 A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
Retinal Vein Occlusion · Macular Edema
Primary: Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence…
Phase 2 N=138 A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Non-Small-Cell Lung Carcinoma
Primary: Recommended Phase 2 Dose (RP2D) of Alectinib
Phase 1 N=32 A Study in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 participants
Phase 2 N=448 A Study in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Dose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population — 34.1; 46.2…
Phase 3 N=610 Combining Lesinurad With Allopurinol in Inadequate Responders
Gout
Primary: Subjects With a Serum Urate (sUA) < 6.0 mg/dL by Month 6. — 0.554; 0.665; 0.233 Proportion of Subjects — p=<0.0001
Phase 4 N=28 A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris
Acne Vulgaris
Primary: Mean Change From Baseline in Total Lesion Count — -26.9 Lesions counted
Phase 3 N=278 Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis
Allergy
Primary: Average Rhinoconjunctivitis Total Symptom Score (ARTSS) — 3.25; 4.51 Units on a scale (range: 0 to 18) — p=0.0010
Phase 1 N=28 A Study of LY2439821 in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Participants With Adverse Events (AEs) [Clinically Significant Events] — 6; 5; 16; 3 participants
Phase 2 N=18 Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease
Cardiac Output, Low
Primary: Blood Pressure. — 6; 5.89 mmHg